Growing community of inventors

St. Louis, MO, United States of America

Huafeng Fang

Average Co-Inventor Count = 10.00

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 4

Huafeng FangXiaoxu Li (2 patents)Huafeng FangDipanjan Pan (2 patents)Huafeng FangKaren L Wooley (2 patents)Huafeng FangMichael John Welch (2 patents)Huafeng FangXiankai Sun (2 patents)Huafeng FangJeffrey L Turner (2 patents)Huafeng FangMatthew L Becker (2 patents)Huafeng FangRaffaella Rossin (2 patents)Huafeng FangJohn-Stephen Taylor (1 patent)Huafeng FangJohn Stephen Taylor (1 patent)Huafeng FangHuafeng Fang (2 patents)Xiaoxu LiXiaoxu Li (21 patents)Dipanjan PanDipanjan Pan (14 patents)Karen L WooleyKaren L Wooley (13 patents)Michael John WelchMichael John Welch (11 patents)Xiankai SunXiankai Sun (7 patents)Jeffrey L TurnerJeffrey L Turner (2 patents)Matthew L BeckerMatthew L Becker (2 patents)Raffaella RossinRaffaella Rossin (2 patents)John-Stephen TaylorJohn-Stephen Taylor (2 patents)John Stephen TaylorJohn Stephen Taylor (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Washington University (2 from 1,585 patents)


2 patents:

1. 9095601 - Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ('PNAs') with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer

2. 8354093 - Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ('PNAs') with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/4/2026
Loading…